Literature DB >> 18537629

Carriership of Factor V Leiden and evolutionary selection advantage.

Pelle G Lindqvist1, Björn Dahlbäck.   

Abstract

Historically, lethal exsanguinations and severe infections have been two major causes of maternal death. Gene mutations that lower the risk of profuse hemorrhage or severe infections would give a survival advantage. A single mutation of coagulation factor V, known as FV Leiden (FVL), can be such a beneficial mutation. FVL is common among Caucasians and today confers an increased risk of thromboembolism. However, the high prevalence of FVL (up to 15%) in the general population suggests that it has given an evolutionary advantage. In this review, we discuss possible mechanisms of the evolutionary survival advantage associated with FVL. In women, FVL confers lower risk of blood loss and profuse hemorrhage in association with delivery and improves the hemoglobin status. In addition, FVL carriers possibly have a survival advantage during sepsis. In conclusion, the high prevalence of FVL may be the result of one or more evolutionary selection advantages.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537629     DOI: 10.2174/092986708784638852

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

1.  An age-related decrease in factor V Leiden frequency among Polish subjects.

Authors:  G Adler; M Parczewski; E Czerska; B Loniewska; M Kaczmarczyk; J Gumprecht; W Grzeszczak; A Szybinska; M Mossakowska; A Ciechanowicz
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

2.  Framing postpartum hemorrhage as a consequence of human placental biology: an evolutionary and comparative perspective.

Authors:  Elizabeth T Abrams; Julienne N Rutherford
Journal:  Am Anthropol       Date:  2011

3.  Survival advantage of heterozygous factor V Leiden carriers in murine sepsis.

Authors:  E Kerschen; I Hernandez; M Zogg; M Maas; H Weiler
Journal:  J Thromb Haemost       Date:  2015-03-31       Impact factor: 5.824

4.  Correlation with Platelet Parameters and Genetic Markers of Thrombophilia Panel (Factor II g.20210G>A, Factor V Leiden, MTHFR (C677T, A1298C), PAI-1, β-Fibrinogen, Factor XIIIA (V34L), Glycoprotein IIIa (L33P)) in Ischemic Strokes.

Authors:  Sener Tasdemir; Haktan Bagis Erdem; Ibrahim Sahin; Lutfi Ozel; Gokhan Ozdemir; Recep Eroz; Abdulgani Tatar
Journal:  Neuromolecular Med       Date:  2016-03-07       Impact factor: 3.843

5.  APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.

Authors:  Sara Sedano-Balbás; Mark Lyons; Brendan Cleary; Margaret Murray; Geraldine Gaffney; Majella Maher
Journal:  BMC Pregnancy Childbirth       Date:  2010-03-10       Impact factor: 3.007

6.  Pathogen entrapment by transglutaminase--a conserved early innate immune mechanism.

Authors:  Zhi Wang; Christine Wilhelmsson; Pavel Hyrsl; Torsten G Loof; Pavel Dobes; Martina Klupp; Olga Loseva; Matthias Mörgelin; Jennifer Iklé; Richard M Cripps; Heiko Herwald; Ulrich Theopold
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

7.  Thrombophilia: 2009 update.

Authors:  Pat Foy; Stephan Moll
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

Review 8.  Thrombophilia and assisted reproduction technology-any detrimental impact or unnecessary overuse?

Authors:  Baris Ata; Bulent Urman
Journal:  J Assist Reprod Genet       Date:  2016-07-16       Impact factor: 3.412

9.  Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey.

Authors:  Serdar Oztuzcu; Sercan Ergun; Mustafa Ulaşlı; Gülper Nacarkahya; Yusuf Ziya Iğci; Mehri Iğci; Recep Bayraktar; Ali Tamer; Ecir Ali Çakmak; Ahmet Arslan
Journal:  Mol Biol Rep       Date:  2014-02-15       Impact factor: 2.316

10.  Factor v leiden and inflammation.

Authors:  Silvia Perez-Pujol; Omer Aras; Gines Escolar
Journal:  Thrombosis       Date:  2012-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.